Claims for Patent: 5,643,746

Summary for Patent: 5,643,746

Title:	Human epidermal gene promoter
Abstract:	The present invention relates to promoter elements from human type I transglutaminase (TGase I) genes for controlled gene expression of both human TGase I and heterologous proteins. These promoter elements permit tissue-specific expression of genes, e.g. for use in human gene therapy and for testing pharmaceutical agents with artificial skin. Additionally, the subject promoter elements can provide differential regulation under physiological conditions or in the presence of exogenously added factors including calcium and retinoic acid.
Inventor(s):	Polakowska; Renata Regina (Pittsford, NY), Goldsmith; Lowell Alan (Pittsford, NY)
Assignee:	Research Corporation Technologies, Inc. (Tucson, AZ)
Application Number:	08/216,219
Patent Claims:	1. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said DNA comprises a BamHI restriction fragment consisting of the nucleotide sequence of bases 485 to 1093 of SEQ ID NO:1. 2. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said DNA comprises an NlaIII restriction fragment consisting of the nucleotide sequence of bases 1563 to 1760 of SEQ ID NO:1. 3. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said DNA comprises an HindIII restriction fragment consisting of the nucleotide sequence of bases 616 to 1574 of SEQ ID NO:1. 4. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said DNA comprises an HindIII-NlaIII restriction fragment consisting of the nucleotide sequence of bases 616 to 1760 of SEQ ID NO:1. 5. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said DNA comprises a BamHI restriction fragment consisting of the nucleotide sequence of bases 485 to 1093 of SEQ ID NO:1, wherein said fragment comprises a polynucleotide sequence encoding a keratinocyte-specific regulatory element and a calcium-responding regulatory element. 6. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said DNA comprises an NlaIII restriction fragment consisting of the nucleotide sequence of bases 1563 to 1760 of SEQ ID NO:1, wherein said fragment comprises a polynucleotide sequence encoding a keratinocyte-specific regulatory element, a calcium-responding regulatory element and a retinoic acid-responding regulatory element. 7. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said DNA comprises an HindIII restriction fragment consisting of the nucleotide sequence of bases 616 to 1574 of SEQ ID NO:1, wherein said fragment comprises a polynucleotide sequence encoding a negative regulatory element which inhibits calcium and retinoic acid responsiveness. 8. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said DNA comprises an HindIII-NlaIII restriction fragment consisting of the nucleotide sequence of bases 616 to 1760 of SEQ ID NO:1, wherein said fragment comprises a polynucleotide sequence encoding a keratinocyte-specific regulatory element, a calcium-responding regulatory element and a retinoic acid-responding regulatory element. 9. An isolated DNA comprising a transcriptional regulatory region from a human type I transglutaminase gene wherein said sequence comprises nucleotides 1 to 1757 of SEQ ID NO:1. 10. A replicable expression vector comprising the DNA of any one of claims 5 or 9 wherein said DNA is operably linked to the coding sequence of a gene product and is thereby capable of effecting expression of said gene product of interest. 11. The vector of claim 10 wherein said gene product is a human type I transglutaminase, a marker gene, or a heterologous gene product of interest. 12. The vector of claim 11 wherein said marker gene is chloramphenicol acetyl transferase, .beta.-glucuronidase, or .beta.-galactosidase. 13. The vector of claim 11 wherein said heterologous gene product is a keratin, an acidic keratin, a basic keratin, an enzyme, an interferon, an interleukin, GM-CSF, G-CSF, M-CSF, a retinoic acid receptor, a steroid hormone receptor, a vitamin D receptor, epidermolysin, filaggrin, loricrin, cystic fibrosis transmembrane receptor, growth hormone, insulin, parathyroid hormone, ACTH, substance P or an endogenous opiate. 14. A host cell comprising the expression vector of claim 10. 15. The host cell of claim 14 wherein said host is a bacterium, a yeast cell or a mammalian cell. 16. The host cell of claim 15 wherein said mammalian cell is a human keratinocyte. 17. A method for keratinocyte-specific expression of a gene product of interest which comprises cultivating a keratinocyte cell which comprises any one of the expression vectors of claims 10-13, for a time and under conditions effective to express said gene product of interest.

Details for Patent 5,643,746

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2014-07-01